Figure 6. CD4CAR NK-92 cells demonstrate anti-leukemic effects in vivo.
NSG mice were sublethally irradiated and intradermally injected with luciferase-expressing KARPAS-299 cells (Day 0) to induce measurable tumor formation. On day 1 and every 5 days for a total of 6 courses, mice were intravenously injected with 5 × 106 CD4CAR NK-92 cells or vector control NK-92 cells. (A) On days 7, 14, and 21, mice were injected subcutaneously with RediJect D-Luciferin and subjected to IVIS imaging. (B) Average light intensity measured for the CD4CAR NK-92 injected mice was compared to that of vector control NK-92 injected mice. (C) On day 1, and every other day after, tumor size area was measured and the average tumor size between the two groups was compared. (D) Percent survival of mice was measured and compared between the two groups.